Botox Application's Moment Of Truth May Come Before Off-Label Showdown
This article was originally published in The Pink Sheet Daily
Executive Summary
In an unsealed filing that notes data problems with the Botox sNDA, FDA contends that Allergan's First Amendment suit could allow companies to promote drugs that have not been shown to be effective.
You may also be interested in...
Four Ways To Draw DDMAC's Ire: In Print, On A Dosing Card, In A Script, And In Person
In a series of letters, FDA cites Lilly, Cephalon, Bayer and Amylin for promotional violations.
Cancer-Genomics Firm Quanticel Debuts With Close Ties To Celgene, And An Exit In Mind
Celgene will get exclusive use of Quanticel's single-cell genomic analysis to tweak its clinical pipeline, and it also has exclusive options to acquire the venture-backed start-up.